Legislation to increase access to breast and cervical cancer screening introduced in the Senate

Early-onset cancer bill introduced in Congress

Asal SayasSen. Ed Markey (D-MA) and Sen. Amy Klobuchar (D-MN) introduced a bill that requires NIH to develop a national strategy to address the rise of cancer in younger adults.

House bill gives NCI $7.4 billion in FY 2027—$110 million above current budget

On June 9, the House Appropriations Committee passed its version of the fiscal year 2027 spending bill for Labor, Health and Human Services, and Education.

June 12, 2026

Vol.52 No.23

By Paul Goldberg

As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded

Last week, Wafik El-Deiry, a cancer researcher at Brown University, showed up at a Senate hearing to talk about what he sees as dangers of the COVID-19 vaccine.

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.

June 05, 2026

Vol.52 No.22

Drugs & Targets

FDA approves Enhertu in HER2+ early breast cancer for both neoadjuvant and adjuvant treatment

FDA approved Enhertu (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer based on results from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials, respectively.

May 22, 2026

Vol.52 No.20

Clinical Roundup

Stage 4 breast cancer has increased in incidence and proportion over the last decade

Researchers found that cases of stage 4 breast cancer are increasing both in incidence and as a proportion of all breast cancer diagnoses, according to findings from an observational study.

May 15, 2026

Vol.52 No.19

Legislation to increase access to breast and cervical cancer screening introduced in the Senate

YOU MAY BE INTERESTED IN

Early-onset cancer bill introduced in Congress

House bill gives NCI $7.4 billion in FY 2027—$110 million above current budget

As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

FDA approves Enhertu in HER2+ early breast cancer for both neoadjuvant and adjuvant treatment

Stage 4 breast cancer has increased in incidence and proportion over the last decade

Renew today!

Subscriber content

Never miss an issue!

Login

Legislation to increase access to breast and cervical cancer screening introduced in the Senate

YOU MAY BE INTERESTED IN

Early-onset cancer bill introduced in Congress

House bill gives NCI $7.4 billion in FY 2027—$110 million above current budget

As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick labThe job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

FDA approves Enhertu in HER2+ early breast cancer for both neoadjuvant and adjuvant treatment

Stage 4 breast cancer has increased in incidence and proportion over the last decade

Never miss an issue!

Login

As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded